Monday, January 18, 2021
Home Latest Pharma-News Oxford Sciences Innovation announces the sale of Base Genomics to Exact Sciences

Oxford Sciences Innovation announces the sale of Base Genomics to Exact Sciences

October 27, 2020: “Base Genomics, an Oxford Sciences Innovation (OSI) portfolio company, has been acquired by Exact Sciences for a total consideration of $410m.

Base Genomics, founded by OSI Entrepreneur in Residence Ollie Waterhouse in 2018, is aiming to set new industry standards for the detection of methylated DNA, used to detect cancer at an early stage.

- Advertisement -

Waterhouse worked alongside Dr Chunxiao Song and Dr Yibin Liu of the Ludwig Institute for Cancer Research Branch at the University of Oxford to develop a new approach to DNA methylation technology – a breakthrough chemical intervention called TAPS.

OSI has financially supported Base Genomics since its inception, by strengthening the team with commercial and scientific expertise.

Through its partnership with Exact Sciences, a specialist in early cancer detection, Base Genomics will be able to accelerate its clinical and commercial development.

Exact Sciences will continue to build on the Base Genomics team in Oxford, with the aim of creating a world-leading research centre for early stage cancer detection.

“I would like to thank OSI for their commitment to Base Genomics over the past two years, supporting us from inception to this next, exciting stage in our journey,” said Ollie Waterhouse, chief executive officer of Base Genomics.

“We are delighted to be joining Exact Sciences, a world leader in early cancer detection that has focused on DNA methylation for over a decade. Together, we look forward to developing a multi-cancer early detection blood test, which could be one of the most impactful oncology products in history,” he added.”

https://www.oxfordsciencesinnovation.com/news/oxford-sciences-innovation-announces-the-disposal-of-base-genomics-to-exact-sciences/

LEAVE A REPLY

Please enter your comment!
Please enter your name here

fifteen + seventeen =

Most Popular

GSK presents positive efficacy data of dostarlimab at ASCO Gastrointestinal Cancers Symposium

January 16, 2021: "GlaxoSmithKline (GSK) plc announced updated data from GARNET cohort F evaluating dostarlimab in mismatch repair-deficient (dMMR) non-endometrial advanced solid...

Bharat Biotech signs agreement with Precisa Medicamentos for supply of ‘COVAXIN™’ to Brazil

January 12, 2020: "Bharat Biotech announced that it has signed an agreement with Precisa Medicamentos for the supplies of COVAXIN™ to Brazil.

What Is a Blockbuster Drug?

What Is a Blockbuster Drug? "Blockbuster drugs are those that generate at least $1 billion of revenue per...

Boehringer Ingelheim and Enara Bio join forces to discover Cancer Immunotherapies

January 12th, 2021: Boehringer Ingelheim and Enara Bio announced that they have entered into a strategic collaboration and licensing agreement to research...